Penicillin binding protein 1 is important in the compensatory response of Staphylococcus aureus to daptomycin-induced membrane damage and is a potential target for β-lactam-daptomycin synergy

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 1, 2016, Pages 451-458

  Berti, Andrew D ^a   Theisen, Erin ^a,b   Sauer, John Demian ^a   Nonejuie, Poochit ^c   Olson, Joshua ^c   Pogliano, Joseph ^c   Sakoulas, George ^d   Nizet, Victor ^d   Proctor, Richard A ^a,b   Rose, Warren E ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; BETA LACTAM ANTIBIOTIC; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CEFACLOR; CEFOTAXIME; CEFOXITIN; CEFTRIAXONE; DAPTOMYCIN; IMIPENEM; MEROPENEM; NAFCILLIN; PENICILLIN BINDING PROTEIN; PENICILLIN BINDING PROTEIN 1; PENICILLIN BINDING PROTEIN 2; PENICILLIN BINDING PROTEIN 3; PENICILLIN BINDING PROTEIN 4; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; ISOPROTEIN; THIENAMYCIN DERIVATIVE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL MEMBRANE; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BACTERICIDAL ACTIVITY; CELLULAR STRESS RESPONSE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; GENETIC TRANSCRIPTION; IN VITRO STUDY; MEMBRANE DAMAGE; METABOLIC STRESS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; CELL MEMBRANE; COMBINATION DRUG THERAPY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; STATISTICAL MODEL;

ANTI-BACTERIAL AGENTS; CEFACLOR; CEFOTAXIME; CEFOXITIN; CEFTRIAXONE; CELL MEMBRANE; DAPTOMYCIN; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GENE EXPRESSION REGULATION, BACTERIAL; IMIPENEM; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MODELS, STATISTICAL; NAFCILLIN; PENICILLIN-BINDING PROTEINS; PROMOTER REGIONS, GENETIC; PROTEIN ISOFORMS; THIENAMYCINS; TRANSCRIPTION, GENETIC;

EID: 84957884064     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02071-15     Document Type: Article

References (36)

1. Rose WE, Schulz LT, Andes D, Striker R, Berti AD, Hutson PR, Shukla SK. 2012. Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity. Antimicrob Agents Chemother 56:5296-5302. http://dx.doi.org/10.1128/AAC.00797-12.
2. Rand KH, Houck HJ. 2004. Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 48:2871-2875. http://dx.doi.org/10.1128/AAC.48.8.2871-2875.2004.
3. Dhand A, Bayer AS, Pogliano J, Yang SJ, Bolaris M, Nizet V, Wang G, Sakoulas G. 2011. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis 53:158-163. http://dx.doi.org/10.1093/cid/cir340.
4. Werth BJ, Sakoulas G, Rose WE, Pogliano J, Tewhey R, Rybak MJ. 2013. Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 57:66-73. http://dx.doi.org/10.1128/AAC.01586-12.
5. Pogliano J, Pogliano N, Silverman JA. 2012. Daptomycin-mediated reorganization of membrane architecture causes mislocalization of essential cell division proteins. J Bacteriol 194:4494-4504. http://dx.doi.org/10.1128/JB.00011-12.
6. Yang SJ, Xiong YQ, Boyle-Vavra S, Daum R, Jones T, Bayer AS. 2010. Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillinresistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect"). Antimicrob Agents Chemother 54:3161-3169. http://dx.doi.org/10.1128/AAC.00487-10.
7. Moise PA, Amodio-Groton M, Rashid M, Lamp KC, Hoffman-Roberts HL, Sakoulas G, Yoon MJ, Schweitzer S, Rastogi A. 2013. Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant β-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment. Antimicrob Agents Chemother 57: 1192-1200. http://dx.doi.org/10.1128/AAC.02192-12.
8. Georgopapadakou NH, Liu FY. 1980. Penicillin-binding proteins in bacteria. Antimicrob Agents Chemother 18:148-157. http://dx.doi.org/10.1128/AAC.18.1.148.
9. Hartman BJ, Tomasz A. 1984. Low-affinity penicillin-binding protein associated with beta-lactam resistance in Staphylococcus aureus. J Bacteriol 158:513-516.
10. Pinho MG, Filipe SR, de Lencastre H, Tomasz A. 2001. Complementation of the essential peptidoglycan transpeptidase function of penicillinbinding protein 2 (PBP2) by the drug resistance protein PBP2A in Staphylococcus aureus. J Bacteriol 183:6525-6531. http://dx.doi.org/10.1128/JB.183.22.6525-6531.2001.
11. Kumar KM, Anbarasu A, Ramaiah S. 2014. Molecular docking and molecular dynamics studies on β-lactamases and penicillin binding proteins. Mol Biosyst 10:891-900. http://dx.doi.org/10.1039/c3mb70537d.
12. Dumitrescu O, Choudhury P, Boisset S, Badiou C, Bes M, Benito Y, Wolz C, Vandenesch F, Etienne J, Cheung AL, Bowden MG, Lina G. 2011. Beta-lactams interfering with PBP1 induce Panton-Valentine leukocidin expression by triggering sarA and rot global regulators of Staphylococcus aureus. Antimicrob Agents Chemother 55:3261-3271. http://dx.doi.org/10.1128/AAC.01401-10.
13. Berti AD, Sakoulas G, Nizet V, Tewhey R, Rose WE. 2013. β-Lactam antibiotics targeting PBP1 selectively enhance daptomycin activity against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 57:5005-5012. http://dx.doi.org/10.1128/AAC.00594-13.
14. Plata KB, Riosa S, Singh CR, Rosato RR, Rosato AE. 2013. Targeting of PBP1 by β-lactams determines recA/SOS response activation in heterogeneous MRSA clinical strains. PLoS One 8:e61083. http://dx.doi.org/10.1371/journal.pone.0061083.
15. Muthaiyan A, Silverman JA, Jayaswal RK, Wilkinson BJ. 2008. Transcriptional profiling reveals that daptomycin induces the Staphylococcus aureus cell wall stress stimulon and genes responsive to membrane depolarization. Antimicrob Agents Chemother 52:980-990. http://dx.doi.org/10.1128/AAC.01121-07.
16. Kuroda H, Kuroda M, Cui L, Hiramatsu K. 2007. Subinhibitory concentrations of beta-lactam induce haemolytic activity in Staphylococcus aureus through the SaeRS two-component system. FEMS Microbiol Lett 268:98-105. http://dx.doi.org/10.1111/j.1574-6968.2006.00568.x.
17. Utaida S, Dunman PM, Macapagal D, Murphy E, Projan SJ, Singh VK, Jayaswal RK, Wilkinson BJ. 2003. Genome-wide transcriptional profiling of the response of Staphylococcus aureus to cell-wall-active antibiotics reveals a cell-wall-stress stimulon. Microbiology 149:2719-2732. http://dx.doi.org/10.1099/mic.0.26426-0.
18. Pereira SF, Henriques AO, Pinho MG, de Lencastre H, Tomasz A. 2007. Role of PBP1 in cell division of Staphylococcus aureus. J Bacteriol 189: 3525-3531. http://dx.doi.org/10.1128/JB.00044-07.
19. Pereira SF, Henriques AO, Pinho MG, de Lencastre H, Tomasz A. 2009. Evidence for a dual role of PBP1 in the cell division and cell separation of Staphylococcus aureus. Mol Microbiol 72:895-904. http://dx.doi.org/10.1111/j.1365-2958.2009.06687.x.
20. Łeski TA, Tomasz A. 2005. Role of penicillin-binding protein 2 (PBP2) in the antibiotic susceptibility and cell wall cross-linking of Staphylococcus aureus: evidence for the cooperative functioning of PBP2, PBP4, and PBP2A. J Bacteriol 187:1815-1824. http://dx.doi.org/10.1128/JB.187.5.1815-1824.2005.
21. Berti AD, Baines SL, Howden BP, Sakoulas G, Nizet V, Proctor RA, Rose WE. 2015. Heterogeneity of genetic pathways toward daptomycin nonsusceptibility in Staphylococcus aureus determined by adjunctive antibiotics. Antimicrob Agents Chemother 59:2799-2806. http://dx.doi.org/10.1128/AAC.04990-14.
22. Cassat JE, Dunman PM, McAleese F, Murphy E, Projan SJ, Smeltzer MS. 2005. Comparative genomics of Staphylococcus aureus musculoskeletal isolates. J Bacteriol 187:576-592. http://dx.doi.org/10.1128/JB.187.2.576-592.2005.
23. Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing; approved standard, 20th informational supplement M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA.
24. Mishra NN, McKinnell J, Yeaman MR, Rubio A, Nast CC, Chen L, Kreiswirth BN, Bayer AS. 2011. In vitro cross-resistance to daptomycin and host defense cationic antimicrobial peptides in clinical methicillin-resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother 55:4012-4018. http://dx.doi.org/10.1128/AAC.00223-11.
25. Sakoulas G, Okumura CY, Thienphrapa W, Olson J, Nonejuie P, Dam Q, Dhand A, Pogliano J, Yeaman MR, Hensler ME, Bayer AS, Nizet V. 2014. Nafcillin enhances innate immune-mediated killing of methicillin-resistant Staphylococcus aureus. J Mol Med (Berl) 92:139-149. http://dx.doi.org/10.1007/s00109-013-1100-7.
26. Jones T, Yeaman MR, Sakoulas G, Yang SJ, Proctor RA, Sahl HG, Schrenzel J, Xiong YQ, Bayer AS. 2008. Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob Agents Chemother 52:269-278. http://dx.doi.org/10.1128/AAC.00719-07.
27. Sakoulas G, Bayer AS, Pogliano J, Tsuji BT, Yang SJ, Mishra NN, Nizet V, Yeaman MR, Moise PA. 2012. Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 56: 838-844. http://dx.doi.org/10.1128/AAC.05551-11.
28. Rose WE, Rybak MJ, Kaatz GW. 2007. Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. J Antimicrob Chemother 60:334-340. http://dx.doi.org/10.1093/jac/dkm170.
29. Akins RL, Rybak MJ. 2000. In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model. Antimicrob Agents Chemother 44:1925-1929. http://dx.doi.org/10.1128/AAC.44.7.1925-1929.2000.
30. Blaser J. 1985. In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives. J Antimicrob Chemother 15(Suppl A):125-130. http://dx.doi.org/10.1093/jac/15.suppl-A.125.
31. Rose WE, Knier RM, Hutson PR. 2010. Pharmacodynamic effect of clinical vancomycin exposures on cell wall thickness in heterogeneous vancomycin-intermediate Staphylococcus aureus. J Antimicrob Chemother 65:2149-2154. http://dx.doi.org/10.1093/jac/dkq292.
32. Barber KE, Werth BJ, Ireland CE, Stone NE, Nonejuie P, Sakoulas G, Pogliano J, Rybak MJ. 2014. Potent synergy of ceftobiprole plus daptomycin against multiple strains of Staphylococcus aureus with various resistance phenotypes. J Antimicrob Chemother 69:3006-3010. http://dx.doi.org/10.1093/jac/dku236.
33. Mishra NN, Bayer AS, Weidenmaier C, Grau T, Wanner S, Stefani S, Cafiso V, Bertuccio T, Yeaman MR, Nast CC, Yang SJ. 2014. Phenotypic and genotypic characterization of daptomycin-resistant methicillin-resistant Staphylococcus aureus strains: relative roles of mprF and dlt operons. PLoS One 9:e107426. http://dx.doi.org/10.1371/journal.pone.0107426.
34. Mehta S, Singh C, Plata KB, Chanda PK, Paul A, Riosa S, Rosato RR, Rosato AE. 2012. β-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives. Antimicrob Agents Chemother 56:6192-6200. http://dx.doi.org/10.1128/AAC.01525-12.
35. Tran TT, Panesso D, Mishra NN, Mileykovskaya E, Guan Z, Munita JM, Reyes J, Diaz L, Weinstock GM, Murray BE, Shamoo Y, Dowhan W, Bayer AS, Arias CA. 2013. Daptomycin-resistant Enterococcus faecalis diverts the antibiotic molecule from the division septum and remodels cell membrane phospholipids. mBio 4:e00281-13. http://dx.doi.org/10.1128/mBio.00281-13.
36. Yang SJ, Nast CC, Mishra NN, Yeaman MR, Fey PD, Bayer AS. 2010. Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms. Antimicrob Agents Chemother 54:3079-3085. http://dx.doi.org/10.1128/AAC.00122-10.